SCHEMBL1198629

SCHEMBL1198629

CCOC(=O)c1cnn(Cc2ncc(-c3cccc(C(F)(F)F)c3)s2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 1/20 0.49
BRAF P15056 2/20 0.44
KCNH2 Q12809 1/20 0.43
GRM5 P41594 1/20 0.42
XPO1 O14980 1/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2B Q13224 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CNR2 P34972 1/20 0.42
SYK P43405 1/20 0.41
CTSA P10619 1/20 0.41
GRM2 Q14416 1/20 0.41
PCSK9 Q8NBP7 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875718 0.89 JMJD6 (0.46) KDM4EGRM2NPSR1NPC1RAB9A
SCHEMBL1198441 0.87 MEN1 (0.50) MEN1KMT2AKCNH2KDM4ECTSA
SCHEMBL12876474 0.86 MEN1 (0.53) MEN1KMT2AMAPTBRAFKCNH2
SCHEMBL1198706 0.86 MEN1 (0.50) MEN1KMT2AMAPTBRAFKCNH2
SCHEMBL1198977 0.85 MEN1 (0.50) MEN1KMT2AMAPTBRAFKCNH2
SCHEMBL1198435 0.85 MAPT (0.49) MEN1KMT2AMAPTBRAFKCNH2
SCHEMBL1197563 0.84 MEN1 (0.53) MEN1KMT2AMAPTBRAFKCNH2
SCHEMBL1197786 0.83 TEAD2 (0.43) MAPTKCNH2KDM4EGRM2CYP1A2
SCHEMBL1198067 0.83 KDM4E (0.49) MEN1KMT2AMAPTKCNH2KDM4E
SCHEMBL1199603 0.82 MAPT (0.54) MEN1KMT2AMAPTBRAFKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885KMT2A 3197/4885MAPT 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.